Nanologica Receives Order for Silica for Preparative Chromatography from US Customer

Nanologica AB (publ) has received an order for the company’s silica for preparative chromatography to a value of approximately TSEK 230. The order comes from a customer in the North American market.

During 2022, Nanologica has completed the up-scaling to large-scale production of the company’s commercial silica for preparative chromatography, NLAB Saga®.  This order is a direct consequence of the company now being able to deliver the volumes of silica required for customers to be able to proceed in the evaluation steps of the material. The silica is evaluated in several stages at different scales before it can be included in the customer’s production.

With large-scale production in place, Nanologica is working intensively to move forward in material evaluation with more customers, in order to be able to sign supply agreements for larger volumes as the next step.

Our first order from the US market gives us further evidence of what we have seen during the launch of our product NLAB Saga® – the interest in and need for our products is great. The sales process in preparative chromatography is long, where the material is evaluated in a number of steps from small scale to full production scale. The fact that we now have access to product on a large scale means that we can proceed with customers in this evaluation with the goal of signing larger supply agreements. It will likely take a bit more time before we are through full-scale evaluation with the first customers, but the future looks very bright and I believe that our business in preparative chromatography within a few years will be able to generate significant profitability for the company”, CEO Andreas Bhagwani comments.

The order consists of several product types and delivery of products is expected during the fourth quarter of this year.


For further information, please contact:

Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail:


About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility of innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Chromatography, the company aims to make insulin and other peptide drugs available to more patients in need, by lowering the cost of manufacturing. In Drug Development, Nanologica develops a unique drug delivery platform for local delivery of drugs to the lung, to provide new treatment options for patients with lung diseases. Nanologica is headquartered in Södertälje, and the company’s share (NICA) is listed for trade on Nasdaq Stockholm Main Market since 29 mars, 2022. For further information, please visit


2022-10-03 Nanologica Receives Order for Silica for Preparative Chromatography from US Customer

Share this: